About half of all people with cystic fibrosis, the most common genetic disorder in the United States, die from a lung disease before they turn 40. A form of pneumonia called Pseudomonas aeruginosa is a likely culprit.
A team of scientists at Boston Children's Hospital has developed the first modeling system for testing age-specific human immune responses to vaccines -- outside the body.
The Food and Drug Administration (FDA) announces it has approved Aemcolo (rifamycin), an antibacterial drug indicated for the treatment of adult patients with travelers’ diarrhea caused by noninvasive strains of Escherichia coli (E. coli), not complicated by fever or blood in the stool.
The National Institutes of Health awarded Tulane University School of Medicine a contract for up to $8.5 million over five years to develop a more effective and longer-lasting vaccine against pertussis, more commonly known as “whooping cough.”
Before patients receive intravenous (IV) antimicrobial infusion therapy outside of the hospital – whether at home, a doctor’s office or a skilled nursing facility – an infectious diseases (ID) specialist should review the order to ensure the most appropriate treatment, suggest updated guidelines
Keeping hospitals clean is a crucial patient safety issue. The importance of the hospital environment in patient care has only recently been recognized widely in infection prevention and control (IPC).
In an international collaboration between Sementis and Enesi Pharma, Sementis Ltd is partnering up with the experts in the field of Zika virus and chikungunya vaccine research at UniSA’s Experimental Therapeutics Laboratory at its Cancer Research Institute to evaluate a needle-free vaccination te
Hepatitis C drugs cure more than 90 percent of patients, but can cost more than $50,000 per patient.
The following is a statement from FDA commissioner Scott Gottlieb, MD, on new steps to strengthen and modernize agency’s oversight and reporting of inspections for sterile injectable drugs:
The Food and Drug Administration (FDA) announces that an emergency use authorization (EUA) has been issued for a rapid, single-use test for the detection of Ebola virus (Zaire ebolavirus).